Adjusted EBITDA increased from €45 million in Q1 2012 to 53 million in Q1 2013 (+18%), the third best quarterly result of Oxea since its inception in 2007.
Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International